Celcuity

Celcuity is a biotechnology company developing and delivering new targeted therapies for cancers involving the PAM (PI3K/AKT/mTOR) pathway.

[Celcuity @celcuity]

$CELC CEO Brian Sullivan will participate in a fireside chat with Citi Equity Analyst Eva Fortea-Verdejo today. Listen to the webcast: https://t.co/TYjtkcyGFF

[Celcuity @celcuity]

$CELC will participate in the Wells Fargo and Citi Investor Conferences next week. Learn more: https://t.co/tQhHLeloWi

[Celcuity @celcuity]

We are very pleased to announce that Celcuity has submitted its supplemental NDA to the FDA for REVTORPYK™ (gedatolisib. You can find more details in the press release: https://t.co/2CMkh3Gmbs
$CELC

[Celcuity @celcuity]

Featured in @CancerNetwrk: a leading oncologist's perspective on the recent FDA approval of a new targeted therapy for patients with HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer.

Read the full article: https://t.co/GYrqy9cADF

[Celcuity @celcuity]

Celcuity reports financial results for the second quarter 2026 and provides a corporate update today. Read our press release here: https://t.co/e2HgbLOAUn
Listen to our webcast conference call today at 4:30 pm ET: https://t.co/ysvwso1TjI
$CELC

[Celcuity @celcuity]

Celcuity will report on its second quarter 2026 financial results this Thursday, August 13, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: https://t.co/ANVQW9JxGe
$CELC

[Celcuity @celcuity]

REVTORPYK™ (gedatolisib) in combination with fulvestrant, w/or/wo palbociclib, is recommended by the NCCN Clinical Practice Guidelines in Oncology as a preferred Category 1 second-line and/or subsequent-line therapy. Details in our press release: https://t.co/cIjr1i0Wq1 $CELC

[Celcuity @celcuity]

#NEWS: The FDA has approved our targeted therapy for patients with HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer following progression on prior therapy. Learn more: https://t.co/5CRq2e4wiO
#FDAApproval
#BreastCancer
$CELC

[Celcuity @celcuity]

Listen in tomorrow morning as Celcuity CEO and co-founder Brian Sullivan participates in a fireside chat presentation with equity research analyst Rich Law the at Goldman Sachs 47th Annual Global Healthcare Conference in Miami. Webcast link: https://t.co/pEDPpWb1I2
$CELC

[Celcuity @celcuity]

Celcuity CEO Brian Sullivan will participate in a fireside chat with Equity Research Analyst Maury Raycroft at the Jefferies Global Healthcare Conference. Listen in: https://t.co/SdTVaUBANf
$CELC #JefferiesHealthcare

[Celcuity @celcuity]

Celcuity reported detailed results for the PIK3CA mutant cohort of the pivotal Phase 3 VIKTORIA-1 trial in patients with HR+/HER2- advanced breast cancer. Read our press release here: https://t.co/8c8yIR8p5R

[Celcuity @celcuity]

$CELC announced that we will host a conference call and live webcast to review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026, at 8:00 a.m. EDT. https://t.co/oKrccneW3x

[Celcuity @celcuity]

We look forward to attending the upcoming conferences in June: Jefferies Global Healthcare Conference in New York and Goldman Sachs 47th Annual Global Healthcare Conference 2026.
For more information: https://t.co/tRBNAzWjqz
$CELC

[Celcuity @celcuity]

$CELC reports financial results for Q1 2026 and provides a corporate update today. Press release: https://t.co/euJ69vBHhF | Webcast at 4:30 pm ET: https://t.co/4wiscp94Z7

[Celcuity @celcuity]

$CELC announces updates to our clinical development plan including expansion of our Phase 3 VIKTORIA-2 clinical trial to include a second study evaluating gedatolisib as 1L treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancer. https://t.co/FKpP3TCZ4U

[Celcuity @celcuity]

$CELC will report on Q1 2026 financial results next Thursday, May 14, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: https://t.co/dPvHaRGIeZ

[Celcuity @celcuity]

Today, we announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with or without palbociclib in patients with HR+/HER2- PIK3CA mutant advanced breast cancer. https://t.co/9iBrTNsRQm

[Celcuity @celcuity]

Celcuity reports financial results for the fourth quarter and full year 2025 and provides corporate update: https://t.co/XlBDYfOHqF
Listen in to our webcast conference call today at 4:30 pm ET: https://t.co/MfOwGgSjdj
$CELC

[Celcuity @celcuity]

$CELC will report on Q4 and full year 2025 financial results next Wednesday, March 25, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: https://t.co/NnkCZ1dPr8

[Celcuity @celcuity]

Results from the Phase 3 VIKTORIA-1 trial were published in @JCO_ASCO. We would like to thank Dr. Sara Hurvitz for serving as a co-primary investigator and for helping us potentially bring this important therapy to patients. Read the manuscript: https://t.co/AcPKxDssq3